Drug
Imc R117c
Imc R117c: highest development phase Phase 1/2, developed by Immunocore. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Immunocore
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMC-R117C NCT06840119 | Phase 1/2 | Cancer |
Latest
No recent events.
Follow Imc R117c on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.